Every material Form 8-K Strata Critical Medical, Inc. has filed with the SEC since May 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Strata Critical Medical reported third-quarter 2026 results, with revenue up 50.3% year-over-year to $74.1 million, driven mainly by Clinical acquisitions, while Logistics revenue fell 3.5%. The net loss from continuing operations narrowed to $7.6 million from $9.7 million, and the company announced a $20 million share repurchase authorization and reiterated its 2026 guidance. For shareholders, the larger revenue base and improved profit measures are offset by the continuing net loss and weaker Logistics results.
Q3 2026 revenue of $74.1 million, up from $49.3 million a year earlier; Logistics revenue down 3.5% to $44.9 million
Net loss from continuing operations of $7.6 million in Q3 2026, versus $9.7 million in Q3 2025
Adjusted EBITDA of $9.6 million, a 13.0% margin, versus $4.2 million (8.5%) a year earlier
$20 million share repurchase authorization announced; 2026 revenue ($285-295 million) and Adjusted EBITDA ($33-35 million) guidance reiterated
Strata reported second-quarter 2026 revenue of $72.5 million, up 60.7% from a year earlier, driven by acquisitions and organic Logistics growth. The net loss from continuing operations widened to $10.5 million, or $0.12 per share, from $3.4 million a year earlier, and included a $5.5 million non-cash charge for changes in fair value of assets and other liabilities. The company raised its 2026 revenue and Adjusted EBITDA guidance but left free cash flow guidance unchanged.
Q2 2026 Adjusted EBITDA was $7.9 million, up from $2.5 million in Q2 2025, with a 10.9% margin.
2026 revenue guidance raised to $285-295 million from $260-275 million; Adjusted EBITDA guidance raised to $33-35 million from $29-33 million.
Free cash flow before aircraft and engine acquisitions guidance unchanged at $15-22 million.
Logistics gross margin fell to 18.4% in Q2 2026 from 20.0% a year earlier; cash and short-term investments were $22.8 million at June 30, 2026.
Strata Critical Medical reported first quarter 2026 results on May 6, 2026, with revenue of $67.4 million, up 87.4% from a year earlier, and net income from continuing operations of $2.4 million compared with a loss of $1.6 million in the prior-year quarter. Adjusted EBITDA was $6.4 million, down from $7.0 million in the fourth quarter of 2025, and the company reiterated its full-year 2026 guidance and completed the bolt-on acquisition of Ohio Valley Perfusion Associates for approximately $1 million.
Total revenue of $67.4 million in Q1 2026 versus $35.9 million in Q1 2025; Logistics revenue rose 32.4% to $47.6 million
Net income from continuing operations of $2.4 million versus a $1.6 million loss a year earlier; Adjusted EBITDA of $6.4 million versus $7.0 million in Q4 2025
2026 guidance reiterated: revenue of $260-275 million, Adjusted EBITDA of $29-33 million, free cash flow before aircraft and engine acquisitions of $15-22 million
Completed acquisition of Ohio Valley Perfusion Associates for approximately $1 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Strata Critical Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →